Monday 24 July 2017

Repercussions of failed drug test for Maria Sharapova could be savage

Maria Sharapova announces her failed drug test at the Australian Open during a press conference in Los Angeles. Photo: Jayne Kamin-Oncea/USA Today
Maria Sharapova announces her failed drug test at the Australian Open during a press conference in Los Angeles. Photo: Jayne Kamin-Oncea/USA Today

Oliver Brown IN LOS ANGELES

Maria Sharapova faces up to a four-year ban from tennis after an astonishing admission last night that she had failed a drug test at this year's Australian Open.

Her voice quavering, the Russian, dressed from head to toe in black, used a hastily convened press conference to disclose that she had tested positive for meldonium - a medication normally used to treat heart conditions.

The World Anti-Doping Agency had added the substance, also called mildronate, to its banned list on January 1 but Sharapova failed to read the revised advice.

The repercussions are likely to be savage for an athlete who earned $23m last year in endorsements alone.

Sharapova will incur a four-year ban from tennis if she is found to have taken meldonium intentionally to improve her performance, and two years if the authorities deem it was unintentional.

For the wealthiest female athlete on the planet, it represents a staggering fall from grace.

Sharapova was the darling of women's tennis and, by a distance, its most marketable property. Now, at the age of 28, the young woman who exploded to prominence with her 2004 Wimbledon triumph as a teenager finds herself engulfed in ignominy.

Medicinal

Sharapova, whose provisional ban will start on March 12, insisted that her use of the drug was purely medicinal, but the ITF's rationale for including meldonium on their banned list was unambiguous.

"Meldonium was added because of evidence of its use by athletes for the intention of enhancing performance," the organisation said.

It was, by any standard, one of the most grimly startling moments tennis has ever known.

Ever since Sharapova's advisors had served notice that she would be making a "major announcement" at noon California time, conjecture had mounted that the five-time major champion would be confirming her intention to retire after playing only three tournaments in the past eight months.

When the ballroom at the LA Hotel Downtown was fitted out with a floor-to-ceiling curtain, murmurs bubbled that Sharapova, ever the corporate creature, was simply about to unveil her latest range of sweets.

But the presence in the room of Sharapova's parents, Yuri and Yelena, hinted that something more dramatic was afoot.

So did the fact that she slunk to centre stage in a black dress - a far cry from her usual vibrant ensembles.

The bleakness of her words were more than a match for her dour choice of fashion. "I have let my fans down, I have let my sport down," she said, her voice trembling. "I face consequences."

The International Tennis Federation disclosed that the positive test took place on the day of Sharapova's last match - a quarter-final defeat to Serena Williams at the Australian Open.

Sharapova explained that she had taken the drug for a combination of reasons, including a magnesium deficiency, an irregular electrocardiogram result, and a family history of diabetes.

"It made me healthy - that's why I continued to take it," she insisted.

In what was comfortably the most chastening two-minute address of her life, Sharapova said: "A few days ago I received a letter from the International Tennis Federation, saying that I had failed a drug test at the Australian Open. I take full responsibility. I have made a huge mistake."

Doctor

Sharapova disclosed that she had been taking the drug, whose trade name is Meldronit, for the past 10 years, after receiving a prescription from her family doctor.

She claimed that she was unaware that it was also known as meldonium until she read the correspondence from the International Tennis Federation about her failed test in Melbourne.

The reaction from the Women's Tennis Federation was swift and sombre.

Steve Simon, the WTA chief executive, said: "I am very saddened to hear this news about Maria. She is a leader and I have always known her to be a woman of great integrity.

"Nevertheless, as Maria acknowledged, it is all players' responsibility to know what they put in their body and if it is permissible. The matter is now in the hands of the Tennis Anti-Doping Programme. The WTA will support the decisions reached through this process."

Tennis has had to confront doping scandals before, but nothing on this scale. Greg Rusedski tested positive for nandrolone in 2003 but was subsequently cleared of any wrongdoing. Mariano Puerta, runner-up at the 2005 French Open, was banned for eight years after taking the stimulant etilefrine.

If Sharapova is seeking any solace at so dispiriting a juncture, she might reflect upon the more recent case of Marin Cilic. The Croatian was given a nine-month ban for a failed test but rebounded to win the 2014 US Open.

Whether Sharapova is capable of such a return is a moot point. Her body has failed her at frequent points of late, especially her deteriorating shoulder. But she left no doubt about her resolve to write another act. "I don't want to end my career this way," she said, tearfully. "I really hope I will be given another chance to play this game."

Even in the midst of her greatest torment, Sharapova, remarkably, struck a seam of the blackest humour. Poking fun at the rumours of retirement, the world No 7 said: "If I was ever going to make an announcement about that, it would not be at a downtown Los Angeles hotel with this rather ugly carpet." (© Daily Telegraph, London)

Telegraph.co.uk

Promoted articles

Editor's Choice

Also in Sport